Entries by Citron Research

, ,

Citron Exposes the Dirty Illegal Secrets of FleetCor, and Proof the Company is Already in Cover-Up Mode

Short Term Price Target = $80 In our first report Citron referred to FleetCor (NYSE:FLT) as “FeeCor” and “FleeceCor”.  The bulls defended the company, claiming FleetCor’s customer fees are legal, not egregious, and most of all are sustainable. In this report Citron clarifies the illegality of FleetCor’s corporate practices, and the lengths the analyst community […]

, ,

Citron Exposes More Undisclosed Relationships at TransDigm

What the Company and Its Analysts Call “A Game” Is Actually Illegal Price Target $140 Citron predicts that after this report makes its rounds, TransDigm’s (NYSE:TDG) days of exploiting and deceiving the Federal Government are numbered. Valeant Pharmaceuticals has recently hit prices that some never thought imaginable. As Citron observes today, at $12 per share, […]

, ,

Express Scripts: Rebate System is a Financial Engineering Kickback Scheme

One company in the healthcare system that deserves to fall to the mighty sword of the new Trump administration is Express Scripts.  (NASDAQ:ESRX) has used their position as the nation’s largest PBM to make itself into “The reason drugmakers sharply raise list prices without a corresponding increase in net price is that PBMs demand higher […]